Comparison of Rivaroxaban and Enoxaparin for preventing venous thromboembolism after spine surgery

Evaluation of the effect of Rivaroxaban and Enoxaparin on preventing the venous thromboembolism after spinal surgery

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200808048333N1

Enrollment

200

Registered

2021-10-29

Start date

2020-08-22

Completion date

Unknown

Last updated

2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Deep Venous Thrombosis And Pulmonary Eembolism. Acute embolism and thrombosis of deep veins of lower extremity

Interventions

Intervention 1: Intervention group: Recipient of Rivaroxaban, patients that receive Rivaroxaban (10mg orally) once daily after surgery to prevent venous thromboembolism, until discharged from hospital

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients undergoing spine surgery No previous history of thromboembolism

Exclusion criteria

Exclusion criteria: Previous history of venous thromboembolism Pregnancy History of cerebrovascular accident

Design outcomes

Primary

Measure	Time frame
Deep Vein Thrombosis. Timepoint: At the begining of the study,14 days after. Method of measurement: Color Doppler Ultrasonography of the lower Extremities.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHamidreza Khayat Kashani

Shahid Beheshti University of Medical Sciences

hamidkhayat@yahoo.com0098217343000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026